August 13, 2026

@michaelokun

Could Tavapadon reshape early Parkinson’s treatment? Could selective dopamine signaling be the next step forward? A dopamine receptor agonist is a medication that stimulates dopamine receptors in the brain to help improve movement. Unlike currently available dopamine agonists that primarily target D2/D3 receptors, Tavapadon selectively targets D1/D5 receptors, an approach designed to preserve motor benefit while potentially reducing some troublesome side effects. Fernandez and colleagues describe in a new paper in The Lancet Neurology evaluating Tavapadon in early Parkinson's disease. Key points: - Tavapadon significantly improved motor symptoms and activities of daily living compared w/ placebo in folks w/ early Parkinson's disease, and benefits emerged as early as 5 weeks. - Tavapadon was generally well tolerated, though nausea, headache and dizziness were more frequent than placebo, and adverse events were most common during dose titration. - Rates of somnolence and impulse control disorders were low, suggesting a potentially differentiated safety profile compared w/ currently available dopamine agonists, though longer follow-up is still needed. My take: We have been waiting for a new dopamine agonist strategy that attempts to separate motor benefit from some of the side effects that have limited the use of older agents. The results are encouraging; however this is not a home run yet. The study lasted only 27 weeks, and we still need long-term data on durability, tolerability, dyskinesias and impulse control disorders. If these findings hold up over time, Tavapadon could become an important new option for treating early Parkinson's disease. Here are 3 points that resonated w/ me: 1- This study reminds us that innovation in Parkinson's disease is not limited to disease modifying therapies. Better symptomatic treatments can meaningfully improve daily life. 2- A once daily medication that improves motor function while maintaining a relatively low rate of sleepiness and impulse control disorders would be welcome news for many folks and their health care providers. 3- The titration period mattered. Many side effects occurred early.